People with hemophilia may benefit from mild exercise to minimize their risk of bleeding according to a study published in the scientific journal Haemophilia.
Search results for:
Mild exercise may reduce bleeding risk in people with hemophilia B. New treatments for hemophilia A and B include an engineered protein targeting activated protein C and a protein replacement therapy using mRNA. Additionally, a self-sealing needle could prevent bleeding from injections for hemophilia patients, and a new method identifies hemophilia A carriers.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
An enzyme called activate protein C (APC), which prevents the formation of blood clots and therefore promotes bleeding could be targeted to treat hemophilia, suggests a study conducted by researcher at the University of Cambridge and the Children’s Hospital of Philadelphia.
Chinese researchers identified a new and simple method to identify women who may be carriers of the gene that causes hemophilia A.
Scientists managed to treat hemophilia B using a new method of protein replacement therapy in a mouse model of the condition.
Researchers from the Republic of Korea developed a new type of needle that is able to completely prevent bleeding following syringe needle puncture. This new type of needle can be invaluable for people with blood clotting disorders like hemophilia where syringe injections can have significant side effects such as uncontrolled bleeding.
In an article titled “Recognizing the need for personalization of hemophilia patient-reported outcomes in the prophylaxis era” published in the scientific journal Haemophilia, researchers reviewed two new tools that are used to measure patient reported outcome measures.
The initial treatment in patients newly diagnosed with hemophilia B should definitely be done in hospital according to a study conducted by scientists in Turkey.
The hemophilia A treatment Nuwiq (simoctocog alfa) is safe and effective for patients with severe disease, both when used on demand or as a preventative treatment, researchers determined in a recent report. The researchers, who analyzed available data on Nuwuq, detailed their finding in the article, “Efficacy and…
A combination of drugs acting on different points of the pain pathway may be beneficial in reducing joint pain in people with hemophilia, according to a review article published in the journal Blood Coagulation and Fibrinolysis.
Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding.